Literature DB >> 20178447

Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer.

Jinn-Shiun Chen1, Kuei-Tien Chen, Wen-Chun Fan, Jau-Song Yu, Yu-Sun Chang, Err-Cheng Chan.   

Abstract

BACKGROUND: Survivin is a member of the family of inhibitor of apoptosis proteins that is overexpressed in several human tumors. Previous studies have found that overexpression of survivin in cancer cells induces an antibody response.
METHODS: We compared 232 serum samples from colorectal cancer (CRC) patients and 365 samples from healthy volunteers using an in vitro enzyme-linked immunosorbent assay to evaluate the survivin autoantibody response in patients.
RESULTS: The sensitivity of the anti-survivin response from patients with CRC was 56.9%, and the specificity was 64.1%. When a cut-off value of 5.0 ng/mL was chosen for carcinoembryonic antigen (CEA) in these same serum samples, the values for sensitivity and specificity were 40.9% and 86.6%, respectively. Combined detection using survivin autoantibodies and CEA produced better sensitivity (51.3%) and specificity (89.9%) compared to the sensitivity of CEA (40.9%) and the specificities of the individual markers (64.1% and 86.6%, respectively). The area under a receiver operating characteristic curve was 0.617 for survivin autoantibodies, 0.630 for CEA and 0.694 for both markers together.
CONCLUSIONS: A positive association between autoantibodies against survivin and preoperative CEA concentrations in sera of patients with CRCs was established. Our results suggest that analysis of both parameters would assist in screening patients with CRC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178447     DOI: 10.1515/CCLM.2010.123

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

1.  Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma.

Authors:  Yukie Hosono; Maki Goto; Daisuke Kobayashi; Kageaki Kuribayashi; Maki Tanaka; Naoki Watanabe
Journal:  Mol Clin Oncol       Date:  2015-02-06

Review 2.  Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests.

Authors:  Le-Le Song; Yue-Min Li
Journal:  World J Gastrointest Oncol       Date:  2016-11-15

3.  Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.

Authors:  Bo Fu; Peng Yan; Shan Zhang; Yan Lu; Li Pan; Wenqiang Tang; Shen Chen; Shuangfeng Chen; Anqi Zhang; Wei Liu
Journal:  Dis Markers       Date:  2018-04-23       Impact factor: 3.434

Review 4.  Biochemical Markers of Colorectal Cancer - Present and Future.

Authors:  Wojciech Jelski; Barbara Mroczko
Journal:  Cancer Manag Res       Date:  2020-06-22       Impact factor: 3.989

5.  The role of microvesicles as biomarkers in the screening of colorectal neoplasm.

Authors:  Mohammad M R Eddama; Rijan Gurung; Konstantinos Fragkos; Paula Lorgelly; Richard Cohen; Marilena Loizidou; Lucie Clapp
Journal:  Cancer Med       Date:  2022-03-27       Impact factor: 4.711

Review 6.  Antibody Diversity in Cancer: Translational Implications and Beyond.

Authors:  Raghuram Reddy; Joel Mintz; Roei Golan; Fakiha Firdaus; Roxana Ponce; Derek Van Booven; Aysswarya Manoharan; Isabelle Issa; Bonnie B Blomberg; Himanshu Arora
Journal:  Vaccines (Basel)       Date:  2022-07-22

7.  Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.

Authors:  Kinga Tóth; Ferenc Sipos; Alexandra Kalmár; Arpád V Patai; Barnabás Wichmann; Robert Stoehr; Henriette Golcher; Vera Schellerer; Zsolt Tulassay; Béla Molnár
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

8.  Bioinformatics Analyses Identify the Therapeutic Potential of ST8SIA6 for Colon Cancer.

Authors:  Chou-Yuan Ko; Tian-Huei Chu; Ching-Cheng Hsu; Hsin-Pao Chen; Shih-Chung Huang; Chen-Lin Chang; Shiow-Jyu Tzou; Tung-Yuan Chen; Chia-Chen Lin; Pei-Chun Shih; Chung-Hsien Lin; Chuan-Fa Chang; Yung-Kuo Lee
Journal:  J Pers Med       Date:  2022-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.